ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: A systematic review and meta‐analysis

摘要: Immune status monitoring of transplant recipients could identify patients at risk acute rejection, infection, and cancer, which are important sources morbidity mortality in these patients. The ImmuKnow assay provides an objective assessment the cellular immune function immunosuppressed Inconclusive results concerning ability test to predict rejection infection have raised concerns about predictive value liver recipients. We conducted a systematic literature review studies published up March 2012 that documented use for study quality was assessed with Quality Assessment Diagnostic Accuracy Studies 2 score. identified 5 analyzing performance rejection. pooled sensitivity, specificity, positive likelihood ratio, diagnostic odds area under summary receiver operating characteristic curve were 83.8% [95% confidence interval (CI) = 78.5%-88.3%], 75.3% (95% CI 70.9%-79.4%), 3.3 2.8-4.0), 14.6 9.6-22.3), 0.824 ± 0.034, respectively, 65.6% 55.0%-75.1%), 80.4% 76.4%-83.9%), 3.4 2.4-4.7), 8.8 3.1-24.8), 0.835 0.060, Heterogeneity low high studies. In conclusion, is valid tool determining further adult Significant heterogeneity across precludes conclusion identifies Liver Transpl 18:1245–1253, 2012. © AASLD.